Neuberg Diagnostics Plans $350 Million IPO in 2026 as Healthcare Market Expands

Neuberg Diagnostics is preparing for a $350 million initial public offering in 2026 as interest in India’s healthcare and diagnostics sector continues to expand. The company has begun discussions with investment banks to advance the listing process and assess the structure of the upcoming offer according to news reports.

Plans for Trivitron Healthcare and Maxivision Eye Hospitals

Beyond Neuberg Diagnostic’s founder confirmed that Trivitron Healthcare and Maxivision Eye Hospitals are also being considered for potential listings according to news reports. The group is reviewing the optimal sequencing and structure for these IPOs, although timelines will depend on market conditions and internal preparations.

Market Context

India’s diagnostics industry is projected to grow at an annual rate of 9.2% and reach $26.7 billion by 2033, supported by rising chronic disease incidence and greater demand for specialised testing. In the broader equity landscape, IPOs have delivered an average return of more than 15% this year, even as about half of newly listed companies are trading below their issue price.

Company Footprint and Recent Funding

Founded in 2017, Neuberg Diagnostics operates across more than 250 Indian cities and has expanded internationally into the UAE, the US and South Africa. Its service portfolio spans genomics, haemato-oncology, histopathology, wellness offerings and rare-disease diagnostics, positioning it as a multi-specialty provider in the diagnostic space.

To strengthen personalised medicine, enhance integrated diagnostic platforms and accelerate inorganic growth, the company recently raised around ₹940 crore from Kotak Alternate Asset Managers. The funding is expected to support expansion plans ahead of the proposed public listing.

Read More: Fortis Healthcare Q2 Net Profit Surges.

Conclusion

Neuberg Diagnostics’ planned IPO marks a significant step in its strategy to expand operations and tap into rising demand across the diagnostics sector. With additional listings under consideration, the group is positioning itself for broader capital market participation in the coming years.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.